MYR's Series B Round

MYR raised a round of funding on October 31, 2014.

MYR is a German biotechnology company developing Myrcludex B, a drug for the treatment of chronic hepatitis B and delta virus infections. The drug inhibits the recently identified HBV receptor on the …

Articles about MYR's Series B Round: